vs
BillionToOne, Inc.（BLLN）与RadNet, Inc.（RDNT）财务数据对比。点击上方公司名可切换其他公司
RadNet, Inc.的季度营收约是BillionToOne, Inc.的6.6倍（$547.7M vs $83.5M）。BillionToOne, Inc.净利率更高（6.8% vs -0.1%，领先6.9%）。BillionToOne, Inc.同比增速更快（117.4% vs 14.8%）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
RadNet是美国领先的放射医疗服务企业，总部位于加利福尼亚州洛杉矶，是美国规模最大的独立固定地址诊断影像中心运营商，按网点数量及年度影像业务收入计均居行业首位。截至2025年，该公司在全美8个州持有或运营超400家影像中心，提供门诊诊断影像服务。
BLLN vs RDNT — 直观对比
营收规模更大
RDNT
是对方的6.6倍
$83.5M
营收增速更快
BLLN
高出102.6%
14.8%
净利率更高
BLLN
高出6.9%
-0.1%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $547.7M |
| 净利润 | $5.7M | $-597.0K |
| 毛利率 | 69.9% | — |
| 营业利润率 | 11.5% | 5.1% |
| 净利率 | 6.8% | -0.1% |
| 营收同比 | 117.4% | 14.8% |
| 净利润同比 | 138.3% | -111.2% |
| 每股收益（稀释后） | $0.10 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNRDNT
| Q4 25 | — | $547.7M | ||
| Q3 25 | $83.5M | $522.9M | ||
| Q2 25 | — | $498.2M | ||
| Q1 25 | — | $471.4M | ||
| Q4 24 | — | $477.1M | ||
| Q3 24 | $38.4M | $461.1M | ||
| Q2 24 | — | $459.7M | ||
| Q1 24 | — | $431.7M |
净利润BLLNRDNT
| Q4 25 | — | $-597.0K | ||
| Q3 25 | $5.7M | $5.4M | ||
| Q2 25 | — | $14.5M | ||
| Q1 25 | — | $-37.9M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $-14.9M | $3.2M | ||
| Q2 24 | — | $-3.0M | ||
| Q1 24 | — | $-2.8M |
毛利率BLLNRDNT
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率BLLNRDNT
| Q4 25 | — | 5.1% | ||
| Q3 25 | 11.5% | 5.2% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | -5.1% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | -32.9% | 7.4% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | 2.6% |
净利率BLLNRDNT
| Q4 25 | — | -0.1% | ||
| Q3 25 | 6.8% | 1.0% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | -8.0% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | -38.8% | 0.7% | ||
| Q2 24 | — | -0.6% | ||
| Q1 24 | — | -0.6% |
每股收益（稀释后）BLLNRDNT
| Q4 25 | — | $0.00 | ||
| Q3 25 | $0.10 | $0.07 | ||
| Q2 25 | — | $0.19 | ||
| Q1 25 | — | $-0.51 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | $-1.47 | $0.04 | ||
| Q2 24 | — | $-0.04 | ||
| Q1 24 | — | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $767.2M |
| 总债务越低越好 | $55.0M | $1.1B |
| 股东权益账面价值 | $-239.5M | $1.1B |
| 总资产 | $327.5M | $3.8B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资BLLNRDNT
| Q4 25 | — | $767.2M | ||
| Q3 25 | $195.2M | $804.7M | ||
| Q2 25 | — | $833.2M | ||
| Q1 25 | — | $717.3M | ||
| Q4 24 | — | $740.0M | ||
| Q3 24 | — | $748.9M | ||
| Q2 24 | — | $741.7M | ||
| Q1 24 | — | $527.0M |
总债务BLLNRDNT
| Q4 25 | — | $1.1B | ||
| Q3 25 | $55.0M | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $834.6M |
股东权益BLLNRDNT
| Q4 25 | — | $1.1B | ||
| Q3 25 | $-239.5M | $1.1B | ||
| Q2 25 | — | $932.3M | ||
| Q1 25 | — | $898.1M | ||
| Q4 24 | — | $902.3M | ||
| Q3 24 | $-242.9M | $895.3M | ||
| Q2 24 | — | $881.0M | ||
| Q1 24 | — | $873.0M |
总资产BLLNRDNT
| Q4 25 | — | $3.8B | ||
| Q3 25 | $327.5M | $3.7B | ||
| Q2 25 | — | $3.5B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $3.0B |
负债/权益比BLLNRDNT
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 1.18× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.17× | ||
| Q1 24 | — | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $84.2M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | — |
| 自由现金流率自由现金流/营收 | 7.7% | — |
| 资本支出强度资本支出/营收 | 8.8% | — |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BLLNRDNT
| Q4 25 | — | $84.2M | ||
| Q3 25 | $13.8M | $52.8M | ||
| Q2 25 | — | $120.3M | ||
| Q1 25 | — | $41.5M | ||
| Q4 24 | — | $42.5M | ||
| Q3 24 | — | $57.4M | ||
| Q2 24 | — | $116.0M | ||
| Q1 24 | — | $17.1M |
自由现金流BLLNRDNT
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率BLLNRDNT
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度BLLNRDNT
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率BLLNRDNT
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | 9.75× | ||
| Q2 25 | — | 8.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.96× | ||
| Q3 24 | — | 17.89× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
